Results 61 to 70 of about 557 (132)

Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism [PDF]

The development of dual agonists for the glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) has been a landmark moment in the treatment of type 2 diabetes and obesity.
Patrick J. Knerr, Jo Edward Lewis, Fiona Mary Gribble, Mireia Montaner, Frank Reimann, Nobuya Inagaki, W. Scott Dodson, Paula-Peace James-Okoro, Norio Harada, Jonathan D. Douros, Danae Nuzzaci   +10 more
core   +4 more sources

A Cross-Species Atlas of the Dorsal Vagal Complex Reveals Neural Mediators of Cagrilintide’s Effects on Energy Balance

Abstract Amylin analogs, including potential anti-obesity therapies like cagrilintide, act on neurons in the brainstem dorsal vagal complex (DVC) that express calcitonin receptors (CALCR). These receptors, often combined with receptor activity-modifying proteins (RAMPs), mediate the suppression of food intake and body
Mette Q. Ludwig, Bernd Coester, Desiree Gordian, Shad Hassan, Abigail J. Tomlinson, Mouhamadoul Habib Toure, Oliver P. Christensen, Anja Moltke-Prehn, Jenny M. Brown, Dylan M. Rausch, Anika Gowda, Iris Wu, Stace Kernodle, Victoria Dong, Mike Ayensu-Mensah, Paul V. Sabatini, Jae Hoon Shin, Melissa Kirigiti, Kristoffer L. Egerod, Christelle Le Foll, Sofia Lundh, Marina Kjærgaard Gerstenberg, Thomas A. Lutz, Paul Kievit, Anna Secher, Kirsten Raun, Martin G. Myers, Tune H. Pers   +27 more
openaire   +2 more sources

Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity

Diabetes mellitus is a devastating chronic metabolic disease. Since the majority of type 2 diabetes mellitus patients are overweight or obese, a novel term—diabesity—has emerged.
Eržen, Stjepan, Gašper Tonin, Jasna Klen, Dubravka Jurišić Eržen, Jurišić Eržen, Dubravka, Klen, Jasna, Stjepan Eržen, Tonin, Gašper   +7 more
core   +1 more source

Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review

Diabetes, Metabolic Syndrome and Obesity
Irma Melyani Puspitasari,1,2,* Dimas Setyadi Putra,2,* Alifa Nisa Deliyana,3 Nurqisthi Iqlima Adiputri,3 Lily Indriani Octovia,4 Sekar Ayu Paramita,5 Rano Kurnia Sinuraya1,2,*1Department of Pharmacology and Clinical Pharmacy ...
Puspitasari IM, Putra DS, Deliyana AN, Adiputri NI, Octovia LI, Paramita SA, Sinuraya RK   +6 more
doaj  

The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines

GLP-1-based therapies have changed the treatment of overweight/obesity. Liraglutide 3.0?mg daily, the first GLP-1 RA approved for treatment of overweight, induced a weight loss of 6?8%, Semaglutide 2.4?mg once weekly improved weight loss to about 12?15%,
Holst, Jens J, Madsbad, Sten
core   +1 more source

The new pharmacological frontiers in the fight against obesity

reservedNegli ultimi anni il mondo farmaceutico sta ricercando nuove terapie per il trattamento dell'obesità. Questi farmaci molto spesso vengono utilizzati anche per il trattamento del diabete; infatti queste due patologie molto spesso sono correlate e
MICHIELETTO, VERONICA
core  

Amylin: A Multi-Functional Pancreatic Hormone-A Review. [PDF]

Diabetes Obes Metab
Le Foll C, Lutz TA.
europepmc   +1 more source

Brain Amylin Signaling, Feeding, and Reward. [PDF]

Compr Physiol
Mietlicki-Baase EG.
europepmc   +1 more source

CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1. [PDF]

Hypertension
Verma S, Böttcher M, Brown P, Dicker D, Rubino D, Sbraccia P, Sharma AM, Smedegaard L, Sørrig R, Garvey WT.   +9 more
europepmc   +1 more source

Future Directions in the Medical Treatment of Obesity: A Narrative Review. [PDF]

Adv Ther
Bassatne A, Rizo I.
europepmc   +1 more source